Positive Data Backs Inivata's T790 Test For Use in Non-Biopsy Lung Cancer Patients
Positive data from a recently published study has backed the use of Inivata's liquid biopsy platform for detecting T790 mutations in lung cancer patients unable to undergo tissue biopsies.
You may also be interested in...
Cambridge University spin-out Inivata has launched a major US clinical validation study to evaluate its liquid biopsy approach against tissue-based diagnostic methods in non-small cell lung cancer patients.
Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.
Barcode Diagnostics is developing a nanotechnology for personalized cancer drug screening. The start-up’s aim is to provide physicians with a tool that matches patients with the most effective medicine, during the different stages of disease.